Long term follow up of patients in the GALA5 trial: an Evaluation of the Tolerability and Feasibility of combining 5-Amino-Levulinic Acid (5ALA) with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma
Description
Design:
The GALA-5 trial was a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Carmustine wafers) in the surgical management of patients with glioblastoma (GBM). This follow on study will obtain mortality data from NHS Digital. For GALA-5, patients gave informed consent for NHS Digital to be contacted so that overall survival data could be collected, so additional consent for this follow on study will not be collected. Patients and sites will not be contacted for the follow up study as all the data collection will be from the NHS Digital. You can find out more about how UCL CTC uses patient information on the UCL CTC's website and the UCL website: http://www.ctc.ucl.ac.uk/Privacy.aspx https://www.ucl.ac.uk/legal-services/privacy
Treatment:
No additional trial treatment is included in this follow up study.
Key inclusion/exclusion criteria:
Only patients that took part in GALA-5 will take part in this long term follow up study. Long term follow up data will only be obtained for patients who were diagnosed post-operatively with glioblastoma during the GALA-5 trial, and are either still known to be alive, or were lost to follow up over the course of the trial.
Duration of recruitment:
n/a
Aim
The objective of this study is to obtain mortality and survival data from NHS Digital for patients on the GALA-5 who may still be alive.